WO2022176677A1 - 筋肉増強用組成物及びその利用 - Google Patents
筋肉増強用組成物及びその利用 Download PDFInfo
- Publication number
- WO2022176677A1 WO2022176677A1 PCT/JP2022/004719 JP2022004719W WO2022176677A1 WO 2022176677 A1 WO2022176677 A1 WO 2022176677A1 JP 2022004719 W JP2022004719 W JP 2022004719W WO 2022176677 A1 WO2022176677 A1 WO 2022176677A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fatty acid
- muscle
- mass
- composition according
- acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 210000003205 muscle Anatomy 0.000 title claims abstract description 35
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 113
- 229930195729 fatty acid Natural products 0.000 claims abstract description 113
- 239000000194 fatty acid Substances 0.000 claims abstract description 113
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 102
- -1 fatty acid esters Chemical class 0.000 claims abstract description 41
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims abstract description 21
- SZHOJFHSIKHZHA-UHFFFAOYSA-N tridecanoic acid Chemical compound CCCCCCCCCCCCC(O)=O SZHOJFHSIKHZHA-UHFFFAOYSA-N 0.000 claims abstract description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 16
- 235000013305 food Nutrition 0.000 claims abstract description 15
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims abstract description 13
- YAQXGBBDJYBXKL-UHFFFAOYSA-N iron(2+);1,10-phenanthroline;dicyanide Chemical compound [Fe+2].N#[C-].N#[C-].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 YAQXGBBDJYBXKL-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000013589 supplement Substances 0.000 claims abstract description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 19
- 230000001965 increasing effect Effects 0.000 claims description 18
- 241001465754 Metazoa Species 0.000 claims description 8
- 210000001087 myotubule Anatomy 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 8
- 235000013361 beverage Nutrition 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 34
- 239000003921 oil Substances 0.000 description 18
- 235000019198 oils Nutrition 0.000 description 18
- 239000003925 fat Substances 0.000 description 17
- 235000019197 fats Nutrition 0.000 description 17
- 238000012360 testing method Methods 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 12
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 11
- 150000002632 lipids Chemical class 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 7
- 239000000843 powder Substances 0.000 description 6
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 6
- 230000000007 visual effect Effects 0.000 description 6
- 241000195493 Cryptophyta Species 0.000 description 5
- 240000007594 Oryza sativa Species 0.000 description 5
- 235000007164 Oryza sativa Nutrition 0.000 description 5
- 229930014626 natural product Natural products 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 235000009566 rice Nutrition 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 102000014429 Insulin-like growth factor Human genes 0.000 description 4
- 235000019482 Palm oil Nutrition 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000008157 edible vegetable oil Substances 0.000 description 4
- 235000021588 free fatty acids Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 239000002540 palm oil Substances 0.000 description 4
- 239000012128 staining reagent Substances 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 3
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- 235000021314 Palmitic acid Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 235000008429 bread Nutrition 0.000 description 3
- 235000013330 chicken meat Nutrition 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 238000012758 nuclear staining Methods 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 235000014593 oils and fats Nutrition 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 150000002327 glycerophospholipids Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000013310 margarine Nutrition 0.000 description 2
- 239000003264 margarine Substances 0.000 description 2
- 150000004667 medium chain fatty acids Chemical class 0.000 description 2
- 230000004220 muscle function Effects 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003863 physical function Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000013580 sausages Nutrition 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 241001306132 Aurantiochytrium Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 102100026148 Free fatty acid receptor 1 Human genes 0.000 description 1
- 102100040133 Free fatty acid receptor 2 Human genes 0.000 description 1
- 102100040136 Free fatty acid receptor 3 Human genes 0.000 description 1
- 102100040134 Free fatty acid receptor 4 Human genes 0.000 description 1
- 102100031416 Gastric triacylglycerol lipase Human genes 0.000 description 1
- 101000912510 Homo sapiens Free fatty acid receptor 1 Proteins 0.000 description 1
- 101000890668 Homo sapiens Free fatty acid receptor 2 Proteins 0.000 description 1
- 101000890662 Homo sapiens Free fatty acid receptor 3 Proteins 0.000 description 1
- 101000890672 Homo sapiens Free fatty acid receptor 4 Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102000043296 Lipoprotein lipases Human genes 0.000 description 1
- 240000005856 Lyophyllum decastes Species 0.000 description 1
- 235000013194 Lyophyllum decastes Nutrition 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101001064310 Rattus norvegicus Gastric triacylglycerol lipase Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 235000021549 curry roux Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- 108010091264 gastric triacylglycerol lipase Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 229940040461 lipase Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 235000020888 liquid diet Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000000199 molecular distillation Methods 0.000 description 1
- 150000002759 monoacylglycerols Chemical class 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000005088 multinucleated cell Anatomy 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- NEGYEDYHPHMHGK-UHFFFAOYSA-N para-methoxyamphetamine Chemical compound COC1=CC=C(CC(C)N)C=C1 NEGYEDYHPHMHGK-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000012830 plain croissants Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 235000013606 potato chips Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 235000012046 side dish Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a muscle building composition and its use.
- Non-Patent Document 1 a Non-Patent Document 1
- fatty acids for muscle building.
- the purpose of the present invention is to use fatty acids to provide a new material that is highly effective in building muscle.
- a muscle-building composition comprising, as an active ingredient, at least one selected from the group consisting of fatty acids having 13, 14, or 15 carbon atoms and fatty acid esters containing the fatty acids.
- the fatty acid is at least one selected from tridecanoic acid, tetradecanoic acid, and pentadecanoic acid.
- the fatty acid ester is a glycerol fatty acid ester.
- [4] The muscle according to any one of [1] to [3] above, containing 0.01% by mass or more and 100% by mass or less of at least one selected from the group consisting of the fatty acid and the fatty acid ester. Enhancement composition.
- [5] The muscle building composition according to any one of [1] to [4] above, which has an effect of increasing muscle fibers.
- An oil and fat composition comprising the muscle building composition according to any one of [1] to [5] above.
- a food or drink containing the muscle building composition according to any one of [1] to [5] above.
- [8] A supplement containing the muscle building composition according to any one of [1] to [5] above.
- [9] An animal feed containing the muscle building composition according to any one of [1] to [5] above.
- fatty acids it is possible to use fatty acids to provide a new material that is highly effective in building muscles.
- the fatty acid used in the present invention may have 13, 14, or 15 carbon atoms, and its origin is not particularly limited. For example, it may be derived from natural products or may be synthetic. Further, it is sufficient that it can be decomposed in vivo and used as a fatty acid having 13, 14, or 15 carbon atoms, and for example, a fatty acid ester containing the above fatty acid may be used. In order to provide them in the form of foods and beverages, supplements, animal feeds, etc., they are preferably prepared from natural products.
- fatty acid having 13, 14, or 15 carbon atoms or the fatty acid ester containing the fatty acid used in the present invention is simply referred to as "fatty acid (C13-15)" or “fatty acid (C13-15) ester” or “fatty acid (C13-15) and/or fatty acid ester thereof”.
- fatty acids (C13-15) include tridecanoic acid (C13:0), tetradecanoic acid (C14:0), and pentadecanoic acid (C15:0).
- the fatty acid is not limited to these saturated fatty acids, and may be an unsaturated fatty acid having a double bond in part of the fatty acid alkyl chain, or a part of the fatty acid alkyl chain may be branched.
- fatty acid (C13-15) esters examples include glycerol fatty acid esters containing the above fatty acids (C13-15), sucrose fatty acid esters, organic acid fatty acid esters, fatty acid alcohol esters, sphingolipids, sorbitan fatty acid esters, polypropylene fatty acid esters, sterol esters. etc. Among these, glycerol fatty acid esters are preferred.
- Glycerol fatty acid ester is an ester having glycerol as a constituent, and specific examples thereof include triacylglycerol, diacylglycerol, monoacylglycerol, glycerophospholipid, glyceroglycolipid and the like.
- fatty acid (C13-15) and/or fatty acid ester thereof one type may be used alone, or a plurality of types may be used in combination.
- enantiomers or diastereomers one single molecular species may be used alone, or multiple molecular species of these isomers may be used in combination.
- the method for obtaining the fatty acid (C13-15) from a natural product is not limited to this. Contains a lot of lipids.
- triglycerides containing fatty acids (C13) and fatty acids (C15) as constituent fatty acids are produced in large amounts. It has been clarified. Therefore, the above fatty acid (C13-15) can be obtained efficiently by using such edible fats or high fat-producing algae as a starting material.
- an organic solvent such as n-hexane, chloroform, diethyl ether, methanol, ethanol, or a mixed organic solvent thereof is added to a dried natural product such as algae, and extracted.
- a triglyceride-containing lipid containing the above fatty acid (C13) and fatty acid (C15) as constituent fatty acids is obtained.
- the resulting triglyceride-containing lipid may be adsorbed with silica gel, acid clay, activated clay, ion-exchange resin, or the like to remove polar lipids to obtain triglycerides.
- the triglyceride-containing lipid may be purified by removing impurities from the triglyceride-containing lipid by a general refining process for vegetable oils, that is, a degumming process, a deacidification process, a decolorization process, or a deodorization process.
- a general refining process for vegetable oils that is, a degumming process, a deacidification process, a decolorization process, or a deodorization process.
- the obtained triglyceride, triglyceride-containing lipid, or triglyceride-containing purified lipid can be subjected to sodium hydroxide treatment or hydrolysis treatment with lipase or the like to liberate fatty acids from the ester structure of glycerol.
- the liberated fatty acid may be further separated and purified by methods such as molecular distillation, urea addition and column chromatography.
- the obtained fatty acid, triglyceride, triglyceride-containing lipid, or triglyceride-containing purified lipid may be used as a raw material for transesterification of triglyceride or ester synthesis.
- the content of the fatty acid (C13-15) and/or the fatty acid ester It is preferable to use a material whose (purity) is increased to 1% by mass or more, more preferably to use a material whose (purity) is increased to 2% by mass or more, and even more preferably to use a material whose (purity) is increased to 5% by mass or more. It is particularly preferable to use materials with an increased content of 10% by mass or more.
- the total content of fatty acids other than fatty acids (C13-15) is, for example, preferably 99% by mass or less, more preferably 95% by mass or less, and 90% by mass. % or less, and particularly preferably 80 mass % or less.
- the quantification of the fatty acid (C13-15) and/or fatty acid ester thereof can be performed by a method well known to those skilled in the art. For example, it is analyzed by the gas chromatograph method, liquid chromatograph method, etc. stipulated in the standard oil analysis test method established by the Japan Oil Chemistry Society, and quantified by applying the concentration when an arbitrarily determined standard sample is analyzed. be able to.
- the quantitative specification of the fatty acid (C13-15) and/or fatty acid ester thereof refers to the total amount of one or more detectable fatty acids (C13-15) and/or fatty acid ester thereof can be treated as
- the muscle-building composition according to the present invention is not limited to this, but may be in the form of a fat composition containing the fatty acid (C13-15) and/or fatty acid ester thereof.
- a fat composition containing the fatty acid (C13-15) and/or fatty acid ester thereof.
- edible oils and fats, excipients, adjuvants, emulsifiers, pH adjusters, etc. are arbitrarily blended as necessary, and any liquid, powder, paste, etc. are prepared by a known method. It can be made into an oil and fat composition in the form of For example, it may be prepared as liquid fat, margarine, fat spread, shortening, powdered fat, etc., which are mainly composed of fat components, or solutions, powders, gels, granules, etc. with a small amount of fat components.
- powdering an auxiliary agent such as corn syrup may be used, and an emulsifier may be added to prepare an emulsified raw material, which may then be powdered.
- Powderization means include spray drying, freeze drying, and the like.
- oils and fats examples include rapeseed oil (including high oleic acid type), soybean oil (including high oleic acid type), palm oil, palm kernel oil, corn oil, olive oil, sesame oil, safflower oil, sunflower oil (high oleic acid type), vegetable oils such as cottonseed oil, rice oil, peanut oil, coconut oil, grapeseed oil, cacao butter, animal oils such as algae oil, beef tallow, lard, chicken fat, and milk fat, medium-chain fatty acid triglycerides, etc. is mentioned.
- fractionated oils medium melting point fractionated oil of palm oil, soft fractionated oil of palm oil, hard fractionated oil of palm oil, etc.
- transesterified oils processed oils such as hydrogenated oils, and the like.
- Edible oils and fats may be used singly or in combination of two or more.
- auxiliary agents include antioxidants, antifoaming agents, emulsifiers, fragrances, flavor imparting agents, pigments, physiologically active substances, and the like. Specific examples include ascorbic acid fatty acid ester, lignan, coenzyme Q, ⁇ -oryzanol, tocopherol, silicone and the like.
- the content of the fatty acid (C13-15) and/or the fatty acid ester contained in the oil and fat composition is not particularly limited.
- the content may be in the range of 0.01% by mass or more and 100% by mass or less, the content may be in the range of 0.1% by mass or more and 100% by mass or less, and the content may be 1% by mass or more and 80% by mass.
- the content may be in the range of 1% by mass or less and 50% by mass or less, and the content may be in the range of 1% by mass or more and 30% by mass or less.
- the content may be in the range of 1% by mass or more and 10% by mass or less, or the content may be in the range of 2% by mass or more and 10% by mass or less.
- the content may be in the range of 10% by mass or more and 30% by mass or less.
- the material itself that provides the fatty acid (C13-15) and/or fatty acid ester thereof may constitute the muscle building composition.
- the muscle building composition according to the present invention uses the above fatty acid (C13-15) and/or fatty acid ester for muscle building.
- “for muscle enhancement” can specifically be an increase or maintenance of muscle mass or an increase or maintenance of muscle strength through the effect of increasing muscle fibers. That is, as shown in the test examples described later, the fatty acid (C13-15) has the effect of increasing the myotube area of myotubes and/or the maximum lateral diameter of myotubes.
- Myotubes are elongated multinucleated cells formed by the fusion of myoblasts, and myofibers are made up of fascicles of myotubes. Increasing the myotube area and/or the maximum transverse diameter of the myotubes by means of this leads to muscle fiber enlargement, which in turn helps to increase and maintain muscle mass and to increase and maintain muscle strength.
- the muscle-building composition according to the present invention can be suitably used, for example, by growing children, middle-aged and middle-aged and elderly healthy people. More specifically, it can be preferably used by healthy people aged 40 and over. In addition, it can be applied not only to humans, but also to livestock such as cows, pigs, chickens, sheep and horses, and non-human animals such as pets such as dogs and cats.
- the muscle-building composition according to the present invention may be used by administering the fatty acid (C13-15) and/or fatty acid ester thereof to a subject, and there are no particular restrictions on the mode of use.
- a fatty acid (C13-15) and/or a fatty acid ester thereof may be contained in a predetermined dosage form and administered orally, applied to the skin, administered by inhalation, or injected intramuscularly. Therefore, it may be administered in a desired form as appropriate.
- the content of the fatty acid (C13-15) and/or fatty acid ester thereof in the dosage form may be appropriately adjusted from the viewpoint of securing the desired dose, and is not particularly limited.
- the content may be in the range of 0.1% by mass or more and 100% by mass or less, the content may be in the range of 1% by mass or more and 100% by mass or less, or 1% by mass or more and 80% by mass or less
- the content may be in the range of 1% by mass or more and 50% by mass or less, and the content may be in the range of 2% by mass or more and 30% by mass or less.
- the content may be in the range of 10% by mass to 30% by mass, and the content may be in the range of 30% by mass to 50% by mass. It can be the amount.
- esters such as lingual lipase present in the oral cavity, gastric lipase present in the stomach, and pancreatic lipase secreted in pancreatic juice.
- esters such as triglycerides contained in blood are decomposed into free fatty acids and glycerol by lipoprotein lipase present on the surface of cells such as muscles.
- some phospholipases liberate free fatty acids from glycerophospholipids, which are esters, by hydrolysis.
- G protein-coupled receptors such as GPR40, GPR41, GPR43 and GPR120 are present on the cell surface. Therefore, from the fatty acid ester of the fatty acid (C13-15) administered to the subject, the fatty acid (C13-15) is released in the body of the subject at an appropriate time, and the effect of the fatty acid in the body can demonstrate
- the dose of the fatty acid (C13-15) and/or fatty acid ester thereof includes the age and health condition of the recipient, the duration of administration, and the duration of administration. It can be determined as appropriate depending on the frequency or the like. Examples of general doses include, for example, a dose in the range of 5 mg or more and 5000 mg or less per day for adults, a dose in the range of 50 mg or more and 3000 mg or less, or a range of 80 mg or more and 2000 mg or less. The dosage may be within the range of 80 mg or more and 1000 mg or less.
- the muscle-building composition according to the present invention may be prepared in the form of, for example, oil and fat compositions, food and drink, supplements, animal feed, etc., together with suitable additives, pharmaceutical ingredients, and the like.
- Typical forms of fat and oil compositions include margarine, butter, fat spread, shortening, and the like.
- Typical forms of food and drink include confectionery (e.g., snacks such as potato chips, baked confectionery such as cookies or cakes, Japanese confectionery, chocolate, candy, etc.), desserts (e.g., pudding, jelly, ice cream, etc.). cream, etc.), breads (e.g. sweet buns, side dish breads, croissants, Danish breads, etc.), noodles (e.g. ramen, udon, pasta, etc.), rice (e.g.
- rice balls, rice porridge, fried rice, etc. cereal foods ( corn flakes, oatmeal, etc.), dairy products (e.g., cheese, yogurt, etc.), processed meat products (e.g., ham, sausage, etc.), processed marine products (e.g., kamaboko, fish sausage, etc.), seasonings (e.g., , mayonnaise, sauce, dressing, etc.), soups (e.g., miso soup, vegetable soup, etc.), processed foods and drinks (e.g., simmered food, fried food, grilled food, curry, etc.), premixed powders (e.g., okonomiyaki powder, fried chicken powder , confectionery mix powder, etc.), solid roux (e.g., curry roux, etc.), beverages (e.g., alcoholic beverages such as beer, sports drinks, lactic acid drinks, soft drinks such as vegetable juices, tea such as black tea, coffee, etc.) , food and drink for nursing care (for example, liquid diet), health
- Typical forms of supplements include tablets, pills, capsules, powders, granules, liquids, syrups, jelly, candies, and the like.
- Typical forms of animal feed include, for example, feed for livestock such as cattle, pigs, chickens, sheep and horses; feed for small animals such as rabbits, rats and mice; Feed for fish and shellfish, feed for pet animals such as dogs, cats, small birds, squirrels, turtles, and the like.
- IGF-1 insulin-like growth factor
- C2C12 cells were placed in a T75 flask using growth medium and cultured in a CO2 incubator (37°C, 5% CO2, humid, hereinafter the same). Medium was changed every 1-2 days. When reaching 80% confluence, detach the cells with 0.25% trypsin-EDTA (Nacalai Tesque) (1 mL) (3 to 5 minutes), add 5 mL of medium, and then centrifuge (180 x g, 5 minutes, room temperature) was performed. The supernatant was removed, the cell pellet was suspended in fresh medium, and seeded in a 96-well black plate at 10,000 cells/0.1 mL/well.
- trypsin-EDTA Nacalai Tesque
- the medium was replaced with a differentiation medium and cultured for 2 days to induce differentiation into myotube cells. After that, the medium was replaced with a differentiation medium (100 ⁇ L) supplemented with the test substance, and the cells were further cultured for 2 days.
- a differentiation medium 100 ⁇ L
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Emergency Medicine (AREA)
- Food Science & Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Animal Husbandry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
[1]炭素数が13、14、又は15である脂肪酸及び該脂肪酸を含む脂肪酸エステルからなる群から選ばれた少なくとも1種を有効成分として含有することを特徴とする筋肉増強用組成物。
[2]前記脂肪酸がトリデカン酸、テトラデカン酸、又はペンタデカン酸から選ばれた少なくとも1種である、上記[1]記載の筋肉増強用組成物。
[3]前記脂肪酸エステルがグリセロール脂肪酸エステルである、上記[1]又は[2]記載の筋肉増強用組成物。
[4]前記脂肪酸及び前記脂肪酸エステルからなる群から選ばれた少なくとも1種を0.01質量%以上100質量%以下含有する、上記[1]~[3]のいずれか1項に記載の筋肉増強用組成物。
[5]筋繊維増大効果を有する、上記[1]~[4]のいずれか1項に記載の筋肉増強用組成物。
[6]上記[1]~[5]のいずれかに記載された筋肉増強用組成物を含む油脂組成物。
[7]上記[1]~[5]のいずれかに記載された筋肉増強用組成物を含む飲食品。
[8]上記[1]~[5]のいずれかに記載された筋肉増強用組成物を含むサプリメント。
[9]上記[1]~[5]のいずれかに記載された筋肉増強用組成物を含む動物用飼料。
〔1.細胞〕
マウス筋芽細胞株C2C12細胞(ATCCカタログ番号CRL-1772)
増殖培地:10%FBS、1%PSを添加したDMEM(高グルコース)
分化培地:2%HS、1%PSを添加したDMEM(高グルコース)
(FBS:ウシ胎児血清(Sigma-Aldrich社)、PS:ペニシリン/ストレプトマイシン混合溶液(ナカライテスク社)、HS:ウマ血清、DMEM(高グルコース):ダルベッコ改変イーグル培地(高グルコース)(Sigma-Aldrich社))
下記に示す各脂肪酸を0.05mM、0.2mM、又は0.5mMの濃度となるように培地に添加した。また、ポジティブコントロールとしては、筋管細胞の形成促進因子であるインスリン様成長因子(IGF-1)(Sigma-Aldrich社)を10ng/mLの濃度となるように培地に添加した。
(1)中鎖脂肪酸;オクタン酸(C8:0)(純度99.2%、Sigma-Aldrich社)とデカン酸(C10:0)(純度99.1%、Sigma-Aldrich社)を75質量%:25質量%の割合で混合
(2)ウンデカン酸(C11:0)(純度99.9%、Sigma-Aldrich社)(3)トリデカン酸(C13:0)(純度99.2%、Sigma-Aldrich社)(4)テトラデカン酸(C14:0)(純度100%、Sigma-Aldrich社)(5)ペンタデカン酸(C15:0)(純度98.8%、Sigma-Aldrich社)
(6)ヘキサデカン酸(C16:0)(純度99%、Sigma-Aldrich社)
(7)ヘプタデカン酸(C17:0)(純度99%、Sigma-Aldrich社)
各脂肪酸をDimethyl sulfoxide(DMSO)(ナカライテスク社)に溶解して濃度0.05M、0.2M、0.5M、又は1Mの溶液を調製し、これらの溶液を培地に1/1000量添加し、目的終濃度0.05mM、0.2mM、0.5mM、又は1mMとした。また、ポジティブコントロールのIGF-1は、0.1NのHClを用いて10μg/mLの濃度に調製し、その溶液を培地に1/1000量添加し、目的終濃度10ng/mLとした。
C2C12細胞は増殖培地を用いてT75フラスコに起眠し、CO2インキュベーター(37℃、5%CO2、湿潤、以下同様)で培養した。培地は1~2日おきに交換した。80%コンフルに到達した時点で0.25%トリプシン-EDTA(ナカライテスク社)(1mL)を用いて細胞を剥離し(3~5分間)、培地を5mL加えた後、遠心(180×g、5分間、室温)を行った。上清を除去し、細胞ペレットを新たな培地に懸濁し、96ウェルblackプレートに10,000cells/0.1mL/ウェルで播種した。翌日、培地を分化培地に交換して2日間培養し、筋管細胞への分化誘導を行った。その後、培地を、被験物質を添加した分化培地(100μL)に交換し、更に2日間培養した。
一次抗体試薬:抗ミオシン重鎖(MHC)抗体(eBioscience社、14-6503-82)
二次抗体試薬:蛍光標識抗マウスIgG2b抗体(Thermo Fisher Scientific社、A21147)
核染色試薬:Hoechst 33342(Thermo Fisher Scientific社、H3570)
被験物質処理後、各ウェルを固定液(4%PFA:パラホルムアルデヒド(ナカライテスク社))100μLに交換し、4℃で15分間インキュベートした後にDulbecco’s Phosphate-Buffered Saline(DPBS)(Thermo Fisher Scientific社)で3回洗浄した。ブロッキング/膜透過液溶液(0.3%TritonX/3%BSA/DPBS)を100μL加え、室温で30分間インキュベートした。一次抗体溶液(一次抗体試薬(300倍希釈)/3%BSA/DPBS)に交換し、4℃で一晩インキュベートした。一次抗体溶液を除去し、ブロッキング液(3%BSA/DPBS)を用いて3回洗浄してから二次抗体溶液(二次抗体試薬(500倍希釈)/0.1%核染色試薬/3%BSA/DPBS)と交換し、室温で2時間インキュベートした。最後にDPBSで3回洗浄し、新しいDPBSと交換してからイメージング解析を行った。
免疫染色した細胞のイメージング解析には、自動細胞画像システム(「Operetta CLS」、PerkinElmer社)を使用し、各ウェル中央部9視野を、10倍対物レンズを用いて撮像後、システムに付属したイメージ解析ソフトウェア(Harmony 4.6)により、抗ミオシン重鎖(MHC)抗体による蛍光領域と核染色試薬による細胞核領域を検出した。なお、筋管細胞は融合細胞であることから、細胞核を3個以上含む融合細胞を筋管細胞と判定し、各視野中の筋管細胞の筋管面積(筋管面積/視野)及び筋管細胞の細胞毎の最大横径(最大横径/筋管細胞)をそれぞれn=5で測定した。横径は細胞に内接する円を描き、その円の直径として求めた。
被験物質無添加群に対する、IGF-1処理群並びに被験物質処理群との有意差を、Dunnett’s検定により検定した。有意水準は両側5%とした。
得られた筋管面積/視野と最大横径/筋管細胞の平均値と標準誤差は、被験物質無添加である対照群の平均値を100%としたときの相対値(%)で表した。なお、表1~表4に示す結果は、それぞれ別異のデータ取得期間に行った結果を示し、同一の被験物質及び最終濃度による試験結果が示される場合、それぞれのデータ取得期間において得られた値を示す。
Claims (9)
- 炭素数が13、14、又は15である脂肪酸及び該脂肪酸を含む脂肪酸エステルからなる群から選ばれた少なくとも1種を有効成分として含有することを特徴とする筋肉増強用組成物。
- 前記脂肪酸がトリデカン酸、テトラデカン酸、又はペンタデカン酸から選ばれた少なくとも1種である、請求項1記載の筋肉増強用組成物。
- 前記脂肪酸エステルがグリセロール脂肪酸エステルである、請求項1又は2記載の筋肉増強用組成物。
- 前記脂肪酸及び前記脂肪酸エステルからなる群から選ばれた少なくとも1種を0.01質量%以上100質量%以下含有する、請求項1~3のいずれか1項に記載の筋肉増強用組成物。
- 筋繊維増大効果を有する、請求項1~4のいずれか1項に記載の筋肉増強用組成物。
- 請求項1~5のいずれかに記載された筋肉増強用組成物を含む油脂組成物。
- 請求項1~5のいずれかに記載された筋肉増強用組成物を含む飲食品。
- 請求項1~5のいずれかに記載された筋肉増強用組成物を含むサプリメント。
- 請求項1~5のいずれかに記載された筋肉増強用組成物を含む動物用飼料。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/275,913 US20240115534A1 (en) | 2021-02-19 | 2022-02-07 | Composition for muscle enhancement and use of same |
JP2023500742A JPWO2022176677A1 (ja) | 2021-02-19 | 2022-02-07 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-025441 | 2021-02-19 | ||
JP2021025441 | 2021-02-19 | ||
JP2021-129674 | 2021-08-06 | ||
JP2021129674 | 2021-08-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022176677A1 true WO2022176677A1 (ja) | 2022-08-25 |
Family
ID=82930471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/004719 WO2022176677A1 (ja) | 2021-02-19 | 2022-02-07 | 筋肉増強用組成物及びその利用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20240115534A1 (ja) |
JP (1) | JPWO2022176677A1 (ja) |
WO (1) | WO2022176677A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102625873B1 (ko) * | 2023-01-27 | 2024-01-16 | 한국생명공학연구원 | 근감소증 예방, 치료 또는 개선용 조성물 및 근감소증을 진단하는 방법 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120142776A1 (en) * | 2009-04-09 | 2012-06-07 | Leinwand Leslie A | Methods and compositions for inducing physiological hypertrophy |
JP2014504858A (ja) * | 2010-12-23 | 2014-02-27 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | 体重減少および維持のためのペットフード組成物および方法 |
US20160287646A1 (en) * | 2015-03-31 | 2016-10-06 | OmniActive Health Technologies (Canada) Limited | Macroalgae compositions, processes for preparation thereof, and uses in sports nutrition |
JP2019172614A (ja) * | 2018-03-28 | 2019-10-10 | 日油株式会社 | 遺伝子発現制御剤及び筋委縮の抑制剤、予防剤又は改善剤 |
JP2019202969A (ja) * | 2018-05-24 | 2019-11-28 | 公立大学法人大阪 | 骨格筋強化剤 |
KR102130240B1 (ko) * | 2019-01-07 | 2020-07-03 | 연세대학교 산학협력단 | 탄소수 14 내지 17의 직쇄 알칸을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생 또는 근감소증 억제효과를 갖는 조성물 |
WO2021086172A1 (en) * | 2019-10-31 | 2021-05-06 | N.V. Nutricia | Composition comprising epa, ma and leucine for improving muscle function |
-
2022
- 2022-02-07 JP JP2023500742A patent/JPWO2022176677A1/ja active Pending
- 2022-02-07 US US18/275,913 patent/US20240115534A1/en active Pending
- 2022-02-07 WO PCT/JP2022/004719 patent/WO2022176677A1/ja active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120142776A1 (en) * | 2009-04-09 | 2012-06-07 | Leinwand Leslie A | Methods and compositions for inducing physiological hypertrophy |
JP2014504858A (ja) * | 2010-12-23 | 2014-02-27 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | 体重減少および維持のためのペットフード組成物および方法 |
US20160287646A1 (en) * | 2015-03-31 | 2016-10-06 | OmniActive Health Technologies (Canada) Limited | Macroalgae compositions, processes for preparation thereof, and uses in sports nutrition |
JP2019172614A (ja) * | 2018-03-28 | 2019-10-10 | 日油株式会社 | 遺伝子発現制御剤及び筋委縮の抑制剤、予防剤又は改善剤 |
JP2019202969A (ja) * | 2018-05-24 | 2019-11-28 | 公立大学法人大阪 | 骨格筋強化剤 |
KR102130240B1 (ko) * | 2019-01-07 | 2020-07-03 | 연세대학교 산학협력단 | 탄소수 14 내지 17의 직쇄 알칸을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생 또는 근감소증 억제효과를 갖는 조성물 |
WO2021086172A1 (en) * | 2019-10-31 | 2021-05-06 | N.V. Nutricia | Composition comprising epa, ma and leucine for improving muscle function |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102625873B1 (ko) * | 2023-01-27 | 2024-01-16 | 한국생명공학연구원 | 근감소증 예방, 치료 또는 개선용 조성물 및 근감소증을 진단하는 방법 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2022176677A1 (ja) | 2022-08-25 |
US20240115534A1 (en) | 2024-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2417971C (en) | Oil/fat composition | |
CA2418350C (en) | Oil/fat composition | |
DE69630195T2 (de) | Verwendung eines ausgleichenden zusatzstoffes für omega-6 und omega-3 ungesättigte fettsäure | |
KR100740564B1 (ko) | 공액화 리놀레산의 디글리세리드가 풍부한 유지조성물 | |
JP6037523B2 (ja) | インスリン抵抗性の予防及び/又は改善剤 | |
AU775774B2 (en) | Peroxisome proliferator-activated receptor agonist | |
WO2014098193A1 (ja) | ペットフード | |
JP2002138296A (ja) | 油脂組成物 | |
TWI389697B (zh) | Improve the composition of lipid metabolism | |
JP2000355538A (ja) | ペルオキシゾーム活性化剤応答性受容体アゴニスト | |
WO2022176677A1 (ja) | 筋肉増強用組成物及びその利用 | |
US20070098761A1 (en) | Processed fat composition for preventing/ameliorating lifestyle-related diseases | |
JP2004075653A (ja) | 体脂肪分解促進剤および飲食物 | |
JP2011057585A (ja) | 抗うつ剤 | |
US9649288B2 (en) | Inhibitor of visceral fat loss in Parkinson's disease patients | |
TW200812569A (en) | Bone density increasing agent | |
JP2006117557A (ja) | 血中アディポネクチン濃度増加剤 | |
US20240156773A1 (en) | Method for increasing blood decanoic acid concentration, blood-decanoic-acid-concentration-increasing agent, pharmaceutical composition, and food composition | |
Cofrades et al. | Potential of fatty components in the valorization of foods by means of health claims | |
JPWO2004022050A1 (ja) | 脂質代謝調整剤および飲食物 | |
JPWO2004064830A1 (ja) | 生活習慣病予防・改善用の油脂加工組成物 | |
JPWO2003074042A1 (ja) | 脱共役蛋白質発現亢進剤 | |
JP2009062364A (ja) | 生体内のプラスマローゲン増加剤 | |
JP2018168139A (ja) | n−3系不飽和脂肪酸を含む中性脂肪値の低減または上昇抑制用の組成物、並びに該組成物の製造におけるn−3系不飽和脂肪酸の使用 | |
JP2003111565A (ja) | 共役脂肪酸含有家禽卵 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22755998 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18275913 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023500742 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22755998 Country of ref document: EP Kind code of ref document: A1 |